Tsoumakidou group’s mission is towards efficient cancer immunotherapies. The overarching goal of the lab is to decipher the landscape of antigen-presenting cells in cancer patients, with the ultimate aim to develop more effective and precise immunotherapies. The laboratory has strong clinical links and works simultaneously with the mouse and human system. By using state of the art -omic technologies, cancer mouse models, patient-derived xenografts, and advanced culture systems, such as cancer organ chips, we study cell subtypes, signaling pathways, genes, regulatory modules and interactions that control antigen presenting cells in cancer. Among the pioneering questions, we are interested in are: 

• How do dendritic cells change as they transition from homeostasis to tumour and tumour draining lymph node microenvironments? 

• How do non-hematopoietic cells, such as fibroblasts, evolve and acquire their exclusive antigen presenting signatures in the tumour microenvironment? 

• Which are the cardinal interactions that signal for T cell priming in tumour draining lymph nodes and tumour tissues?